• Hydroxyethyl Starch 40 or 130 API Raw Material
  • Hydroxyethyl Starch 40 or 130 API Raw Material
  • Hydroxyethyl Starch 40 or 130 API Raw Material
  • Hydroxyethyl Starch 40 or 130 API Raw Material
  • Hydroxyethyl Starch 40 or 130 API Raw Material
  • Hydroxyethyl Starch 40 or 130 API Raw Material

Hydroxyethyl Starch 40 or 130 API Raw Material

Function: Blood System Agents
Certification: GMP
Grade Standard: Medicine Grade
Type: Chemical Reagent
State: Solid
Volatile: Not Volatile
Customization:

Contact Supplier

Gold Member Since 2018

Suppliers with verified business licenses

Manufacturer/Factory

Basic Info.

Model NO.
CAS: 9005-27-0
Manufacturer
Yes
Transport Package
Carton or Drum
Trademark
SHIMEN
Origin
Hebei China
Production Capacity
500000

Product Description

Hydroxyethyl Starch

Generic Name: Hydroxyethyl Starch

CAS: 9005-27-0

Indication: This product is a plasma volume expansion agent.  For the treatment and prevention of hypovolemia or shock associated with surgery, hemorrhagic shock, trauma, traumatic shock, infection, septic shock, burn, burn shock;  Reduce the need for blood supply during surgery and economize on blood use: for example, acute isovolemic hemodilution (ANH);  Therapeutic hemodilution.  

Hydroxyethyl Starch 40 or 130 API Raw Material
SSY Group Limited, established in 1948, principally specializes in R&D, manufacture, and sale of a widerange of pharmaceutical products, including various dosage forms such as intravenous injections, tablets, capsule, ampoules, APIs and medical packaging materials.The main subsidiaries of SSY are as follows
Shijiazhuang No 4 Pharmaceutical Co, Ltd
Hebei Guangxiang Pharmaceutical Co, Ltd.
Hebei Guolong Pharmaceutical Co, Ltd
Jiangsu Best New Medical Material Co, Ltd.

Hebei Hanlin Bio-tech Co., Ltd.
With more than 70-year development, our products
have been sold to both domestic and overseas markets up to more than 80 countries and regions. 


Hebei Guangxiang Pharmaceutical Co., Ltd. is a super-large pharmaceutical enterprise, with 3 billion RMB investment and an area of 1000mu(equals to about 667,000m2) in the Biomedical Industrial Park of Cangzhou Bohai New Area. It seizes the timely opportunity of Beijing-Tianjin-Hebei integrated development and firmly relies on the abundant capital, R&D strength and brand influence of SSY Group. Concentrating on API, intermediate compounds and bio-pharmaceutical preparations, its main products are API series products, metronidazole, nifedipine, theophylline, aminophylline, azithromycin, abidol and other series of products and biomedical preparations.

The manufacturing of main products among them- API series products replaces traditional intermittent production into intelligent continuous production with advanced process equipment, automation and information technology, greatly improving production efficiency.

 

Send your message to this supplier

*From:
*To:
avatar Miss Mary Ma
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now